The latest headlines across every section, pulled from official and open-access sources.
The NHS has hit its target for the number of patients waiting 18-weeks thanks to the biggest improvement in waiting times since the launch of the iPad. In March, 65.3% of patients were waiting 18-weeks, as the waiting list fell by over 312,000 last year, the largest year-on-year reduction in 16 years. The improvement in […]
Transcript - Update on CDC's Hantavirus Response 5/14/2026
There is an outbreak of chikungunya in Mauritius. You can protect yourself by preventing mosquito bites.
Hundreds more children with muscle-wasting condition spinal muscular atrophy (SMA) are to be offered potentially “life-changing” therapy on the NHS which could help them live years longer and attend primary school. From today, 2 innovative treatments for SMA – nusinersen and risdiplam – will be made routinely available on the NHS in England following an access scheme to collect more evidence, giving hundreds of families long term-certainty. NHS […]
This week, we present a promising new therapy for dermatomyositis, evolving approaches to stroke care, the prevention of Covid-19 after household exposure, and new treatments for kidney disease. We review inflammatory myopathies and follow a complex case of multisystem illness. Perspectives discuss AI and uncertainty in clinical care, health equity, the forces shaping affordability in health care, and on unpacking the ordinary.
by Erkison Ewomazino Odih, Jabir A. Abdulahi, Anne V. Amulele, Matthew Bates, Eva Heinz, Weiming Hu, Kajal Jain, Rindidzani Magobo, Courtney P. Olwagen, John M. Tembo, Tolbert Sonda, Jonathan Strysko, Caroline C. Tigoi, Kyle Bittinger, Jennifer Cornick, Ebenezer Foster-Nyarko, Wilson Gumbi, Steven M. Jones, Chileshe L. Musyani, Carolyn M. McGann, Ahmed M. Moustafa, Patrick Musicha, James C. L. Mwansa, Moreka L. Ndumba, Thomas D. Stanton, Donwilliams O. Omuoyo, Oliver Pearse, Laura T. Phillips, Paul J. Planet, Charlene M. C. Rodrigues, Fatou Secka, Kirsty Sands, Erin Theiller, Allan M. Zuza…
by Joël Mossong Whom we meet shapes how infections spread. Where earlier focus of mathematical epidemiology was on incorporating age, more recent work has begun to reveal the importance of socioeconomic aspects for understanding and managing future epidemics. In this Perspective, Joël Mossong discusses the importance of understanding social contacts and how they have evolved for infectious disease modeling, and the need to factor in additional considerations such as ethic and socioeconomic backgrounds.
The world is falling short on health targets, with progress uneven, slowing, and in some areas reversing, according to the World Health Statistics 2026 report, published today by the World Health Organization (WHO).
Source: Centers for Disease Control and Prevention Related MedlinePlus Pages: Reproductive Hazards
Incorrect Product Formulation: product did not contain insulin as listed in the label. — Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles · Class II · Ongoing · 1 bag
Lack of assurance of Sterility: potential product contamination — CareFusion 213, LLC · Class II · Ongoing
Lack of assurance of Sterility: potential product contamination — CareFusion 213, LLC · Class II · Ongoing
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. — Ajanta Pharma Ltd. · Class II · Ongoing · 312,894 packs
Chemical contamination; presence of lead and lithium above specification — Acella Pharmaceuticals, LLC · Class II · Ongoing · 6,336 bottles
Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test — JB Chemicals and Pharmaceuticals Ltd · Class II · Ongoing · 675 bottles
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. — Ajanta Pharma Ltd. · Class II · Ongoing
Subpotent drug — Unichem Pharmaceuticals USA Inc. · Class III · Ongoing
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit — Breckenridge Pharmaceutical, Inc. · Class II · Ongoing
Presence of Particulate Matter. — B BRAUN MEDICAL INC · Class I · Ongoing
Lack of Assurance of Sterility: Potential leaks from perforations in bags. — Fresenius Medical Care Holdings, Inc. · Class II · Ongoing
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. — Teva Pharmaceuticals USA, Inc · Class II · Ongoing
Lack of Assurance of Sterility: Potential leaks from perforations in bags. — Fresenius Medical Care Holdings, Inc. · Class II · Ongoing
CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. — Ajanta Pharma Ltd. · Class II · Ongoing
Undeclared Yellow #5 — Silver Moon LP dba Loard's Ice Cream · Class II · Ongoing